Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Horizon Therapeutics
Deal Size : $65.0 million
Deal Type : Acquisition
Details : The facility, which is located in an IDA Ireland business park, includes a filling line and lyophiliser, or freeze dryer, that can be used for both Horizon’s commercial medicines, including its rare disease biologics TEPEZZA, KRYSTEXXA and UPLIZNA and ...
Brand Name : Tepezza
Molecule Type : Large molecule
Upfront Cash : $65.0 million
June 17, 2021
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Horizon Therapeutics
Deal Size : $65.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
